Stockreport

UroGen Pharma Reports Strong Preliminary Jelmyto® Sales for Second Quarter 2021

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
PDF 73% growth in net product revenue over 1Q 2021 to approximately $13.0 million in 2Q 20212Q 2021 operating expenses anticipated in the range of $33 to $38 millionFull 2Q [Read more]